Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020
Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2
FreeStyle Libre 2 Cleared by FDA as iCGM
Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases
Improving Equitable Access to Continuous Glucose Monitors for Alabama's Children with Type 1 Diabetes: A Quality Improvement Project
Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards
FreeStyle Libre 2 Continuous Glucose Monitor
ADA: Real-world data show lower A1c levels with Abbott's FreeStyle Libre CGM in Type 2 diabetes
FreeStyle Libre 3: World's Smallest Sensor
Dexcom G6 CGM System for Personal Use
FreeStyle Libre 2 System (CGM)
Diabetes Technology Meeting 2020 - Trisha Shang, Jennifer Y. Zhang, B. Wayne Bequette, Jennifer K. Raymond, Gerard Coté, Jennifer L. Sherr, Jessica Castle, John Pickup, Yarmela Pavlovic, Juan Espinoza, Laurel H. Messer
Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications
FreeStyle Libre 2 Continuous Glucose Monitor
FreeStyle Libre 2 Reader - Healthcare Home Medical Supply USA
2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes
Abbott® Freestyle Libre 2 Sensor - Continuous Glucose Monitoring Device (CGM) - Advanced Diabetes Supply®
